Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Chronic kidney disease (CKD) affects approximately 37 million Americans, and many overlap with type 2 diabetes and obesity — the exact population using GLP-1 medications. A landmark 2024 trial changed everything about how nephrologists view semaglutide for CKD patients. Here’s what you need to know.
The FLOW Trial: A Turning Point for Kidney Disease
The FLOW trial (Evaluate Renal Function with Semaglutide Once Weekly) was a landmark phase 3 trial published in the New England Journal of Medicine in 2024. It enrolled 3,533 patients with type 2 diabetes and CKD (eGFR 25–75 mL/min/1.73m²) randomized to semaglutide 1mg weekly or placebo.
The trial was stopped early — because semaglutide was working so well that continuing the placebo arm was deemed unethical.
| Outcome | Semaglutide vs Placebo |
|---|---|
| Primary kidney composite endpoint | 24% risk reduction |
| Kidney failure (dialysis/transplant) | Significantly reduced |
| eGFR decline ≥50% | Significantly reduced |
| Cardiovascular death | Reduced |
| All-cause mortality | Reduced |
The primary composite endpoint — sustained ≥50% decline in eGFR, dialysis, kidney transplant, or renal/cardiovascular death — was reduced by 24% with semaglutide. This is on par with, or exceeds, other kidney-protective drug classes like SGLT2 inhibitors.
How Does Semaglutide Protect the Kidneys?
The mechanisms are thought to be both direct and indirect:
| Mechanism | How It Helps Kidneys |
|---|---|
| Blood sugar control | Reduces glucotoxicity damage to kidney tubules and glomeruli |
| Blood pressure reduction | Lower BP reduces hyperfiltration stress on nephrons |
| Weight loss | Reduces obesity-related glomerular hypertension |
| Anti-inflammatory effects | GLP-1 receptors in the kidney may reduce local inflammation |
| Albuminuria reduction | Reduces protein leakage, a marker of kidney damage |
Is Semaglutide Safe for People with Kidney Disease?
Semaglutide is largely renally safe — it is primarily metabolized by proteolysis, not through the kidneys, meaning dose adjustments are generally not required based on kidney function alone. This contrasts with metformin, which accumulates in severe renal impairment and requires dose reduction or discontinuation.
| CKD Stage | eGFR (mL/min/1.73m²) | Semaglutide Use |
|---|---|---|
| Stage 1–2 | >60 | No restrictions |
| Stage 3a–3b | 30–59 | Generally safe; monitor |
| Stage 4 | 15–29 | Use with caution; FLOW data supports benefit |
| Stage 5 / Dialysis | <15 | Limited data; discuss with nephrologist |
The FLOW trial included patients down to eGFR 25 mL/min/1.73m², demonstrating benefit even in moderate-to-severe CKD. However, GI side effects may be more pronounced in patients with reduced kidney function, and dehydration from vomiting or nausea can be more dangerous in CKD — adequate hydration monitoring is important.
What About Ozempic vs Wegovy Dosing for CKD?
The FLOW trial used Ozempic at the 1mg weekly dose — the diabetes dose, not the higher obesity dose. This is an important nuance. The kidney-protective data is based on this dose. Whether higher doses (Wegovy 2.4mg) provide additional renal benefit beyond the diabetes dose is not yet established by large trial data.
Semaglutide vs SGLT2 Inhibitors for Kidney Disease
| Drug Class | Key Trial | Kidney Risk Reduction | Notes |
|---|---|---|---|
| Semaglutide (GLP-1) | FLOW | 24% primary endpoint reduction | New landmark; added to CKD guidelines |
| Canagliflozin (SGLT2i) | CREDENCE | 30% risk reduction | First dedicated CKD trial for SGLT2i |
| Dapagliflozin (SGLT2i) | DAPA-CKD | 39% risk reduction | Included non-diabetic CKD |
| Empagliflozin (SGLT2i) | EMPA-KIDNEY | 28% risk reduction | Broad CKD population |
The FLOW results position semaglutide alongside SGLT2 inhibitors as a kidney-protective agent. Combination therapy (GLP-1 + SGLT2i) is now being explored as a potentially additive approach for patients with both diabetes and CKD.
Frequently Asked Questions
Can you take Ozempic if you have kidney disease?
Yes, for most stages of CKD. The FLOW trial demonstrated that semaglutide 1mg weekly actually protects kidney function in CKD patients with type 2 diabetes. Discuss with your nephrologist and prescriber given your specific eGFR and clinical situation.
Does semaglutide affect creatinine or eGFR?
Semaglutide has been shown to slow the rate of eGFR decline in CKD patients, meaning it preserves kidney function over time. Short-term minor creatinine fluctuations can occur, especially if GI side effects cause dehydration — stay hydrated.
Is Ozempic better than metformin for CKD?
For kidney protection, semaglutide now has stronger evidence than metformin. Metformin is actually contraindicated in severe CKD (eGFR below 30) due to lactic acidosis risk. Semaglutide remains usable and beneficial across a broader range of kidney function.
What is the FLOW trial?
The FLOW trial was a landmark phase 3 RCT published in 2024 showing that semaglutide 1mg weekly reduced the risk of kidney failure and cardiovascular death by 24% in patients with type 2 diabetes and CKD. The trial was stopped early due to overwhelming benefit.
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.
📋 Compare Top GLP-1 Providers — Find Your Best Option